[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastrointestinal-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastrointestinal-hemorrhage":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,55,87,121,149,173],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100650771","histoacryl-used-for-embolization-of-thoracoabdominal-artery-bleeding-100650771",false,"NCT07753005","HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding","Observational, Prospective, Multicenter Study on HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding (TAB)","HEAL","Inclusion Criteria:\n\n* Active thoracoabdominal arterial bleeding diagnosed by endoscopy, catheter angiography, or computed tomography angiography (CTA).\n* Planned embolization treatment using Histoacryl® as the sole embolic agent for the target lesion.\n* No endoleak following thoracic endovascular aortic repair (TEVAR) or endovascular abdominal aortic repair (EVAR).\n* Patients with malignant tumors must have an expected survival of at least 1 month.\n* Written informed consent obtained from the patient or a legally authorized representative.\n\nExclusion Criteria:\n\n* Previous embolization in the target vascular territory.\n* Known allergy or hypersensitivity to n-butyl cyanoacrylate (NBCA), Lipiodol®, or related treatment components.\n* Use of adjunctive embolic agents in the same target location.\n* Planned surgical treatment after embolization as part of a predefined two-step treatment strategy.\n* Severe septicemia.\n* Participation in another clinical trial.\n* Target vessels unsuitable for safe Histoacryl® injection.\n* Empiric embolization without identification of a target bleeding location.\n* Pregnancy, with the exception of patients treated for postpartum hemorrhage.","ALL","18 Years",{"count":20,"type":21},176,"ESTIMATED","OBSERVATIONAL","This observational study will collect information from adult patients in Japan who are treated with Histoacryl® to stop bleeding from arteries in the chest or abdomen, in order to better understand how well the treatment works and how safe it is during routine medical care.",[25,26,27,28],"Hemorrhage","Gastrointestinal Hemorrhage","Hemoptysis","Postpartum Hemorrhage",[30,31,32,33,34,35,36,37,38,39,40,41],"Embolization","Endovascular embolization","Histoacryl","N-butyl cyanoacrylate","NBCA","Hemostasis","Interventional radiology","Thoracoabdominal artery bleeding","Transcatheter arterial embolization","Arterial embolization","Acute arterial hemorrhage","Visceral Aneurysm","NOT_YET_RECRUITING","2026-08-06",{"date":45,"type":46},"2026-08-07","ACTUAL",{"date":48,"type":21},"2026-09-30",{"date":50,"type":21},"2028-06",{"name":52,"class":53},"Aesculap AG","INDUSTRY",11,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100650600","phase-2-trimebutine-maleate-for-enhancing-gastric-visualization-in-acute-upper-gastrointestinal-bleeding-100650600","NCT07749300","Trimebutine Maleate for Enhancing Gastric Visualization in Acute Upper Gastrointestinal Bleeding","Role of Trimebutine Maleate in Enhancing Endoscopic Gastric Visualization in Patients With Acute Upper Gastrointestinal Bleeding: A Double-Blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* Clinical evidence of AUGIB: Hematemesis, coffee-ground vomiting or melena.\n* Planned urgent upper gastrointestinal endoscopy within 24 hours.\n\nExclusion Criteria:\n\n* Known gastric outlet obstruction.\n* Previous gastric surgery.\n* Pregnancy or lactation.\n* Allergy to Trimebutine Maleate.\n* Chronic use of prokinetic medications.",{"count":63,"type":21},100,"INTERVENTIONAL",[66,67],"PHASE2","PHASE3","Acute upper gastrointestinal bleeding is a medical emergency that requires an urgent upper endoscopy to locate and treat the source of the bleeding. Often, retained blood and clots in the stomach make it difficult for the endoscopist to clearly see the stomach's anatomical structures.\n\nThis study aims to evaluate if administering a medication called Trimebutine Maleate before the endoscopy can help empty the stomach of residual blood and improve the doctor's view. Trimebutine Maleate is a widely prescribed medication that regulates gastrointestinal movement and has a favorable safety profile compared to other medications used for this purpose.\n\nResearchers will include 100 adult patients experiencing acute upper gastrointestinal bleeding who are scheduled for an urgent endoscopy within 24 hours of presentation. Participants will be randomly assigned to receive either 50 mg of intravenous Trimebutine Maleate or a matching placebo (saline solution) 60 to 90 minutes before their procedure. All participants will continue to receive standard medical treatment for their bleeding according to normal hospital protocols.\n\nThe primary goal of the study is to compare the clarity of the stomach view between the two groups using a standardized Gastric Visualization Score. The research team will also measure how often the exact bleeding source is successfully identified, the total duration of the procedure, and whether patients require a repeat endoscopy or a stomach washout (gastric lavage).",[70,71,26],"Acute Upper Gastrointestinal Bleeding","Upper Gastrointestinal Bleeding",[73,74,75,76,77],"Trimebutine Maleate","Trimebutine","Gastric Visualization","Endoscopy","Esophagogastroduodenoscopy","2026-08-01",{"date":43,"type":46},{"date":81,"type":21},"2026-09",{"date":83,"type":21},"2027-10",{"name":85,"class":86},"Assiut University","OTHER",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":97,"conditions":98,"keywords":104,"overallStatus":110,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":120},"100605528","tips-for-complicated-portal-hypertension-related-to-porto-sinusoidal-vascular-disease-100605528","NCT07163689","TIPS for Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease","TIPS for the Management of Complicated Portal Hypertension Related to Porto-Sinusoidal Vascular Disease","TIPS-PSVD","Inclusion Criteria:\n\n* PSVD group :\n* Patient with PSVD according VALDIG criteria\n* TIPS for digestive hemorrhage on portal hypertension\n* TIPS for refractory ascite\n* TIPS for portal vein thrombosis\n* Cirrhosis group with PH : (appaired by age, sexe, type of PH complications)\n* Confirmed cirrhosis with :\n* TIPS for digestive hemorrhage on portal hypertension\n* TIPS for refractory ascite\n* TIPS for portal vein thrombosis\n\nExclusion Criteria:\n\n* no PSVD confirmed diagnosis\n* Budd Chiari syndrome\n* Rendu Osler disease; Heart failure\n* Fontan; Sarcoïdosis\n* Schistosomiase\n* Congenitale liver fibrosis\n* Abernathy syndrome\n* Tumor infiltration by lymphoma\n* Bone graft",{"count":96,"type":21},360,"Porto-sinusoidal Vascular Disease (PSVD) is characterized by a portal hypertension (PH) without cirrhosis. This can induce PH complications, like digestive hemorrhage from esophageal or gastric varices, ascites, or even portal thrombosis. Due to the rarity of MVPS, the treatment of complications of portal hypertension is modeled on the methods used in cirrhotic portal hypertension with non-cardio-selective beta blockers, endoscopic ligations or diuretics in first line therapy, as proposed by the Baveno VII recommendations. In complicated or refractory forms of PH in PSVD, the place of TIPS is also discussed, as in the field of cirrhosis. However, the experience of TIPS in PSVD is limited, reported in case reports and small specifically dedicated series. No predictive factors for survival or recurrence and tolerance were well known. A larger study with control group is needed in order to better know the right time and the right indication for the use of TIPS in complicated PH PSVD-related.\n\nThe study will be retrospective, multicentric involving tertiary university French centers, expert in the management of TIPS. Patients white TIPS-PSVD will be compared with historical patients with TIPS-cirrhose, matched on age, sexe, indication of TIPS. The study will not comprise new intervention, only observational in a real life condition",[99,100,101,102,103,26],"TIPS","Portal Hypertension","Porto-Sinusoidal Vascular Disease","Refractory Ascite","Esophageal Varices",[99,105,106,107,108,109],"Portal hypertension","Porto-Sinusoidal Vascular disease","refractory ascite","esophageal varices","gastrointestinal hemorrhage","RECRUITING","2025-11-18",{"date":113,"type":46},"2025-11-19",{"date":115,"type":46},"2025-05-16",{"date":117,"type":21},"2025-12",{"name":119,"class":86},"Centre Hospitalier Universitaire, Amiens",1,{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":64,"phases":130,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":4},"100593932","phase-4-life-saving-treatment-with-dry-plasma-for-massive-bleeding-in-an-pre-hospital-setting-100593932","NCT07012863","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting","Life-saving Treatment With Dry-plasma for Massive Bleeding in an Pre-hospital Setting - - a Randomized Controlled Study","Inclusion Criteria:\n\n* Patients with clinical signs of bleeding which also triggers resuscitation with crisalloids acording to standard care protocol.\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age.\n* Patients who lack clinical signs of major bleeding.",{"count":129,"type":21},650,[131],"PHASE4","The overall goal of this clinical trial is to study how prehospital transfused dry plasma affect outcomes in terms of mortality as well as complications and coagulation status of patients in or about to develop bleeding shock.\n\nResearchers will compare dry plasma to standard care to see if dry plasma improves survival compared to crystalloid fluid in prehospital patients with heavy bleeding.",[134,135,26,136,137,138],"Bleeding","Aortic Rupture","Obstetric Bleeding","Blunt Injury","Penetrating Injury","2025-09-16",{"date":141,"type":46},"2025-09-17",{"date":143,"type":21},"2026-01-01",{"date":145,"type":21},"2027-09-30",{"name":147,"class":148},"Vastra Gotaland Region","OTHER_GOV",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100583529","rapid-diagnostic-technology-for-augib-based-on-analysis-of-vocs-in-exhaled-breath-100583529","NCT06877507","Rapid Diagnostic Technology for AUGIB Based on Analysis of VOCs in Exhaled Breath","Rapid Diagnostic Technology for Acute Upper Gastrointestinal Bleeding Based on Analysis of Volatile Organic Compounds (VOCs) in Exhaled Breath","VOCsAUGIB","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Clinical suspicion of AUGIB (e.g., hematemesis, melena);\n3. Fasting ≥4 hours;\n4. Signed informed consent.\n\nExclusion Criteria:\n\n1. Severe pulmonary dysfunction or recent lung infection (within 1 week);\n2. Cardiac\u002Frenal failure or disseminated intravascular coagulation;\n3. Contraindications to endoscopy;\n4. High-risk conditions (e.g., massive ascites);\n5. Alcohol consumption within 24 hours;\n6. Pregnancy.",{"count":158,"type":21},200,"This study aims to develop a non-invasive and rapid diagnostic technology for acute upper gastrointestinal bleeding (AUGIB) by analyzing volatile organic compounds (VOCs) in exhaled breath. Clinically confirmed patients will be divided into three groups (no bleeding, minor bleeding, major bleeding) based on endoscopic findings. VOC profiles will be analyzed to construct a predictive model, validated for sensitivity and specificity (both targets ≥0.7). This approach addresses the limitations of endoscopy in emergency or resource-limited settings, improving diagnostic efficiency and reducing mortality.",[161,26],"Volatile Organic Compound",[161,70,163],"Exhaled Breath","2025-03-10",{"date":166,"type":46},"2025-03-14",{"date":168,"type":21},"2025-03-20",{"date":170,"type":21},"2025-07-20",{"name":172,"class":86},"Beijing 302 Hospital",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":180,"sex":181,"minAge":182,"maxAge":183,"enrollmentInfo":184,"targetDuration":185,"studyType":22,"phases":4,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100558591","diagnosis-and-clinical-presentation-of-iliac-graft-enteric-fistula-a-case-report-100558591","NCT06553105","Diagnosis and Clinical Presentation of Iliac Graft-Enteric Fistula: A Case Report","Department of Radiology, School of Medicine, 5th Azar Hospital, Gorgan, Golestan, Iran","Inclusion Criteria:\n\nn\u002Fa\n\nExclusion Criteria:\n\nn\u002Fa",true,"MALE","40 Years","50 Years",{"count":120,"type":21},"10 Days","Abstract\n\nIntroduction:\n\nAorto-enteric fistula (AEF) is a life-threatening complication arising from abnormal connections between the gastrointestinal tract and major arteries. One uncommon type, iliac artery-enteric fistula (IEF), can occur following vascular interventions such as arterial stent-graft placement.\n\nCase Presentation:\n\nWe report the case of a 47-year-old male presenting with hematemesis and abdominal pain, who was diagnosed with an iliac graft-enteric fistula. Timely recognition and management were crucial for a favorable outcome.\n\nClinical Discussion:\n\nDiagnosing AEFs remains challenging, requiring a multidisciplinary approach and high clinical suspicion. While computed tomography angiography (CTA) is commonly used for diagnosis, its sensitivity may be limited, emphasizing the importance of integrating clinical history and findings. Management strategies vary based on etiology and patient status, with surgery being pivotal.\n\nConclusion:\n\nAorto-enteric fistula, which can arise from a thrombosed graft, presents diagnostic challenges due to its rare formation. In patients with a history of vascular interventions and gastrointestinal bleeding, AEF should be considered. This case underscores the need for heightened awareness among healthcare professionals regarding AEF diagnosis and management to reduce severe morbidity, mortality, and prolonged hospital stays.",[188,189,190,26,191],"Case-report","Diagnosis","Digestive System Fistula","Iliac Graft-Enteric Fistula",[193],"case-report; CT scan; Diagnosis; Digestive System Fistula; Gastrointestinal Hemorrhage; Iliac Graft-Enteric Fistula.","2024-08-10",{"date":196,"type":46},"2024-08-14",{"date":198,"type":21},"2024-08-11",{"date":200,"type":21},"2024-08-13",{"name":202,"class":86},"Golestan University of Medical sciences"]